inactivation, promotor methylation or loss of heterozygosity (LOH) (4-7). Mice defective in the mismatch repair gene, PMS2-deficient (PMS2 -/-) mice are hypersensitive to N-MSH2 or MLH1, are susceptible to intestinal tumors as well methyl-N-nitrosourea (MNU)-induced thymic lymphomas as thymic lymphomas and skin tumors (8-13). Moreover, these based on the failure to initiate mismatch repair (MMR) mice were reported to show accelerated adenomatous polyposis at O 6 -methylguanine:T mismatches formed after MNU coli (APC) gene mediated intestinal tumorigenesis (13,14 evidence of progression to carcinoma in these adenomas (15). in either case to an increased rate of tumor production. In the present study, PMS2 ⍣/-mice and their littermate
inactivation, promotor methylation or loss of heterozygosity (LOH) (4) (5) (6) (7) . Mice defective in the mismatch repair gene, PMS2-deficient (PMS2 -/-) mice are hypersensitive to N-MSH2 or MLH1, are susceptible to intestinal tumors as well methyl-N-nitrosourea (MNU)-induced thymic lymphomas as thymic lymphomas and skin tumors (8) (9) (10) (11) (12) (13) . Moreover, these based on the failure to initiate mismatch repair (MMR) mice were reported to show accelerated adenomatous polyposis at O 6 -methylguanine:T mismatches formed after MNU coli (APC) gene mediated intestinal tumorigenesis (13,14).
exposure. However, heterozygous PMS2 knockout
However, deficiency in PMS2 does not predispose mice to (PMS2 ⍣/-) mice do not develop spontaneous tumors, sugintestinal tumors during the first 17 months of life (10). Recent gesting that they have sufficient MMR function to prevent studies have demonstrated that homozygous deficiency for genomic instability. We hypothesized that in PMS2 ⍣/-mice, PMS2 predisposed Min mice, heterozygous for the APC gene, exogenous carcinogens may either mutationally knockout to develop approximately three times the number of intestinal the remaining normal allele leading cells to develop adenomas and four times the number of colon adenomas tumors or introduce sufficient DNA adducts and misrelative to Min and PMS2 ϩ/-/Min mice. However, there was no matches to overload the lower capacity for MMR, leading evidence of progression to carcinoma in these adenomas (15). in either case to an increased rate of tumor production. In the present study, PMS2 ⍣/-mice and their littermate
To understand and further interfere with the tumorigenesis PMS2 ⍣/⍣ mice were monitored for tumor incidence in HNPCC patients, heterozygous mice should closely resemble following MNU treatment. Mice were given 50 mg MNU/ the condition of HNPCC patients. However, mice heterozygous kg i.p. when 5 weeks old. They demonstrated a similar for PMS2 (PMS2 ϩ/-) and PMS2 ϩ/-/Min mice failed to show an incidence of thymic lymphomas, suggesting that expression increased rate of tumor formation compared with PMS2 ϩ/ϩ of the single normal PMS2 allele is sufficient to protect the and Min mice, respectively (15). Similarly, MSH2 ϩ/-and thymus and implying that a single dose of MNU may not MSH2 ϩ/-/Min mice also did not demonstrate accelerated APCefficiently knock out the remaining PMS2 allele in the mediated intestinal tumorigenesis (14), although 40% more thymus. Surprisingly, PMS2 ⍣/-mice were significantly extra-intestinal tumors were seen in the older MSH2 ϩ/-mice more likely to develop intestinal tumors-both adenomas than in the control group of wild-type animals (16). Recently and adenocarcinomas-after MNU than were PMS2 ⍣/⍣ it was reported that 14% of the heterozygous MLH1 knockout mice (2.34 ⍨ 0.34 tumors per mouse versus 1.34 ⍨ 0.25 mice (MLH1 ϩ/-) developed gastrointestinal (GI) tumors, and tumors per mouse; P < 0.05). The intestinal tumors were that the GI tumor incidence increased 7-fold when the located mainly in the small intestine. However, these tumors Apc1638N mutant was also present (13). in both the PMS2 ⍣/-mice and PMS2 ⍣/⍣ mice did not show
In the present study, the effect of N-methyl-N-nitrosourea microsatellite instability characteristic of loss of MMR.
(MNU) on PMS2 ϩ/-mice was investigated. PMS2 knockout These results suggest that a single normal PMS2 allele mice were generated in 129 ES cells and chimeric mice were can protect thymus but not intestine from MNU carcinopropagated as heterozygous mice in the C57BL/6 backgenesis. Organ-specific factors might influence MMRground (10). The genotypes of all the mice were determined mediated resistance to methylating agents. Heterozygous by PCR amplification of tail DNA. Primers used were P1 PMS2 knockout mice may be used as a promising animal (5Ј-TTCGGTGACAGATTTGTAAATG-3Ј), P2 (5Ј-TTTACmodel for intestinal tumorigenesis studies involving GGAGCCCTGGC-3Ј) and P3 (5Ј-TCACCATAAAAATAGenvironmental carcinogens.
TTTCCCG-3Ј), resulting in an~300 bp product for the wildtype allele and an~180 bp product diagnostic of a targeted allele as reported previously (10). Except for mice in the control groups, all experimental mice received a single i.p. DNA mismatch repair (MMR) plays an important role in injection of MNU, 50 mg/kg body wt, at 5 weeks of age. Mice the prevention of tumorigenesis (1) . In humans, defective were carefully observed for 1 year. Mice that developed thymic mismatch repair system is causative of hereditary non-polyposis lymphoma typically had respiratory distress, and were killed thymic lymphomas were massive, encasing the heart and the Here we confirmed that expression of the single normal PMS2 allele is sufficient to protect the T fixed in 10% buffered formalin after they were inflated and washed with saline. All tumor-like lesions were recorded and cells in the thymus from spontaneous and MNU-induced tumors, indicating that a single dose of MNU does not mutate later confirmed by histopathological examination. All other tissues were also fixed in 10% buffered formalin and were the remaining PMS2 allele in the thymus, and thus an induced PMS2-deficient state does not occur. Interestingly, PMS2 ϩ/-routinely processed for light microscopy examination. The sections were cut at 3 µm and stained with hematoxylin and mice were significantly more likely to develop intestinal tumors-both adenomas and adenocarcinomas-after MNU than eosin (H&E). Statistical significance was assessed by the χ 2 test and Fisher's exact test.
were PMS2 ϩ/ϩ mice. Since PMS2 ϩ/-mice do not develop spontaneous thymic A total of 115 MNU-treated PMS2 ϩ/Ϫ mice, 73 MNUtreated PMS2 ϩ/ϩ mice, and 49 untreated PMS2 ϩ/Ϫ mice and lymphomas and intestinal tumors, but are sensitive to MNUinduced intestinal tumorigenesis, PMS2 ϩ/-mice may be useful 35 untreated PMS2 ϩ/ϩ mice were observed in the present study. There were no significant differences in overall as a model to study environmental carcinogenic factors. This issue deserves further investigation using chronic sub-acute or survival between PMS2 ϩ/-and PMS2 ϩ/ϩ mice, both in the treated and untreated groups, as shown in Figure 1 . The low dose of carcinogen by oral route to mimic the human natural environmental carcinogen exposure. PMS2 ϩ/-mice showed a significantly higher incidence of intestinal tumors including both adenomas and adenoOne of the questions raised by our results was whether the PMS2 ϩ/-mice would show loss of the normal allele at carcinomas if they survived Ͼ20 weeks after treatment (Figure 2) , and had higher tumor multiplicity (2.34 Ϯ 0.34 the MNU exposure, as occurs in humans with the HNPCC syndrome, who inherit a single mutant allele of one of the tumors per mouse in PMS ϩ/-mice versus 1.34 Ϯ 0.25 tumors per mouse in PMS2 ϩ/ϩ , P Ͻ 0.05; Table I ). Most of the mismatch repair genes and who develop a malignancy with loss of the remaining allele. To investigate the status of the intestinal tumors were located in the small intestine as a small depressed or ulcerous lesions (Table I; Figure 3 ), which remaining normal PMS2 allele in the tumors, microsatellite instability (MSI) analysis was performed in the 24 MNUwere difficult to distinguish from lymph follicles without histopathological examination. The histopathology demoninduced intestinal tumors in PMS2 ϩ/-mice and seven tumors in PMS2 ϩ/ϩ mice, using selective UV radiation fractionation strated that most of the lesions were non-invasive adenomas and some of them were adenocarcinomas with aggressive (SURF) microdissection procedures and subsequent PCR as described (17). Briefly, relatively pure populations of 200-400 invasion (Table I; Figure 4) .
No spontaneous thymic lymphomas were found in the cells (covered by a SURF dot) were selected from each intestinal tumor or from normal small intestine mucosa and untreated control PMS2 ϩ/-and PMS2 ϩ/ϩ mice (data not shown). Following MNU treatment, PMS2 ϩ/-and PMS2 ϩ/ϩ the extracted DNA was diluted before PCR to determine the presence of novel sized microsatellite alleles. The microsatellite mice demonstrated a similar incidence of thymic lymphoma development, as shown in Figure 5 .
locus used for this assay was DXmit129, a CA-repeat locus on mouse chromosome X. No changes in repeat lengths were PMS2 ϩ/-/Min mice (15). However, widespread microsatellite instability is probably not a major factor leading to accelerated detected from the approximately 20 alleles measured from each tumor. Since many human colorectal adenomas as well aberrant crypt focus and adenoma development in MSH2 -/-/ Min mice. Somatic APC mutations and loss of heterozygosity as normal tissue from MSH2 -/-mice do not display microsatellite instability when analyzed with standard (non-dilution) of APC are responsible for the additional intestinal tumors (14). Loss of heterozygosity of the Min allele was also observed detection techniques (12,18-20), it is difficult to detect MSI except by dilution to single molecules prior to PCR. Prior in 25 of 29 (86%) of the intestinal tumor samples analyzed in PMS2 ϩ/-/Min mice (15). Loss of both copies of the APC gene, analysis (17) demonstrated that altered allele lengths are readily detected at the locus, DXmit129, even in the normal mucosa either by somatic mutations or by inactivation of the second allele, appears to be a prerequisite for intestinal tumor developof 7-week-old PMS2 -/-mice using the established SURF microdissection procedures. As a characteristic of MMR defiment in human and Min mice (21-23). Interestingly, in a different MSH2-deficient model, while ciency, MSI is detected in PMS2-deficient mouse tissue and both adenomas and normal mucosa from PMS2 -/-/Min mice, MSH2 ϩ/-mice had an elevated extra-intestinal tumor incidence that rarely correlated with loss of the wild-type MSH2 allele, while stable microsatellite sequences were observed in both adenomas and surrounding normal mucosa from Min and loss of the wild-type MSH2 allele was found in a significant that MSI was negative in the intestinal tumors from MNUtreated PMS2 ϩ/-mice. Since our MSI assay is highly sensitive, our data suggest that mismatch repair was intact for the MNUinduced intestinal tumors, which developed between 48 and 53 weeks after MNU injection, and that the normal PMS2 allele was not inactivated by a single MNU treatment. In colon tumors of HNPCC patients, MSI was predominantly found in carcinomas rather than adenomas (24) , indicating that in HNPCC, loss of MMR is a relatively late event occurring in adenomas and accelerating progression to carcinomas. PMS2 ϩ/-mice may be useful as a model to study the mechanisms that contribute to the development of MMRdeficient intestinal tumors in HNPCC patients. The mechanisms of GI tumor development and lymphoid tumor development are clearly distinct in both humans and mice. Since PMS2 -/-mice do not develop spontaneous intestinal tumors, they do not appear to accumulate sufficient mismatches in intestine mucosa cell DNA to result in gene mutations or deletions in genes critical to intestinal carcinogenesis such as APC. However, carcinogen exposure may surpass this threshold to induce GI tumors. Because of the long latency required for induction and progression of GI tumors and the hypersensitivity of PMS2 -/-mice to MNUinduced lymphomas (25,26), PMS2 -/-mice are not suitable for MNU-induced GI carcinogenesis studies. However, in a separate study reported in abstract form (27), we have found that PMS2 -/-mice are hypersensitive to induction of intestinal tumors after exposure to another methylating agent, azoxymethane, a colon carcinogen.
Mutagenic mismatched base pairs may be produced by DNA polymerase misinsertion during DNA replication or may be induced following base modification by environmental mutagens. We propose the following mechanism for MNU- which O 6 -methylguanine (O 6 -meG) is the most important (28-30). O 6 -meG in double-stranded DNA preferentially pairs with thymine (T) instead of cytosine (C) by any of the polymerases, producing O 6 -meG:T mispairs (31, 32) . During the subsequent round of repair or replication synthesis, this results in a G→A transition mutation. In MMR-proficient cells, O 6 -meG:T mispairs are recognized, resulting in singlestrand patch formation opposite the O 6 -meG because this is in the newly synthesized strand. But, during repair synthesis, a polymerase incorporates a T opposite each O 6 -meG. This futile cycle is associated with DNA strand breaks whenever the single strand extends to replication site, either leading to induction of apoptosis and cell death or non-homologous recombination and chromosomal rearrangements at the site of the patches. For this reason, both G→A mutations and chromosomal rearrangements may contribute to the carcinogenesis of methylating agents in MMR-competent animals. As an additional factor present in the thymus, compensatory In the setting of MMR deficiency, the exact transforming lymphomas were found in the untreated control PMS2 ϩ/-and PMS2 ϩ/ϩ mice (data not shown).
event that follows methylating agent induced DNA damage remains ill defined. Since MMR is not initiated at the site of MNU-induced O 6 -meG DNA lesions, cells survive with high levels of DNA methylation. As a consequence, G→A point fraction (8-18%) of the intestinal tumors in MSH2 ϩ/-/Min mice (16). The status of MMR in the intestinal tumors mutations are formed in certain oncogenes such as K-ras or tumor suppressor genes such as APC and may be oncogenic. originating from MLH1 ϩ/-and MLH1 ϩ/-/APC1638N mutant mice was not investigated (13). In the present study, we found This tolerance to methylating agents is scored as drug PMS2 ⍣/-mice are hypersensitive to GI tumors 9. Prolla,T.A., Baker,S.M., Harris,A.C., Tsao,J.L., Yao,X., Bronner,C.E., resistance in cell lines and tumors (33, 34) , but our data indicate Zhang,B., Gordon,M., Reneker,J., Arnheim,N., Shibata,D., Bradley,A. and that the large number of G→A mutations results in a marked 
